Safety, Tolerability, and Effect of Food on the Pharmacokinetics of Iloperidone (HP 873), a Potential Atypical Antipsychotic

@article{Sainati1995SafetyTA,
  title={Safety, Tolerability, and Effect of Food on the Pharmacokinetics of Iloperidone (HP 873), a Potential Atypical Antipsychotic},
  author={Stephen M. Sainati and John W. Hubbard and Eric M Chi and Kenneth W. Grasing and Martin Brecher},
  journal={The Journal of Clinical Pharmacology},
  year={1995},
  volume={35}
}
Iloperidone (HP 873) is a D2 and 5‐HT2 receptor‐antagonist that is under development as a potential atypical antipsychotic agent. Two studies on iloperidone evaluated its safety and tolerability, made a preliminary pharmacokinetic assessment of single 3‐ and 5‐mg doses, and determined the effect of food on its tolerability and pharmacokinetics in healthy volunteers after single 3‐mg doses. Iloperidone was well absorbed orally in fasted subjects. The Cmax occurred approximately 2 to 3 hours… 
The Effects of Food on the Pharmacokinetics of a Formulated ACP‐103 Tablet in Healthy Volunteers
TLDR
The effects of food on the pharmacokinetics of ACP-103 after a single oral administration were evaluated in healthy male subjects and the results were compared to those after administration of the solution of ACp-103.
Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion
  • L. Citrome
  • Medicine
    Expert opinion on drug metabolism & toxicology
  • 2010
TLDR
The tolerability profile of iloperidone is noteworthy in terms of modest weight gain, no medically important changes in lipid and glucose, little in the way of prolactin elevation, and an absence of extrapyramidal adverse effects, including akathisia.
Iloperidone: A new drug for the treatment of schizophrenia.
  • Sally A. Arif, Melissa Mitchell
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2011
TLDR
Iloperidone may be a viable and safe option for the treatment of schizophrenia in adult patients, especially for patients who cannot tolerate other antipsychotic agents.
Influences of CYP2D6*10 polymorphisms on the pharmacokinetics of iloperidone and its metabolites in Chinese patients with schizophrenia: a population pharmacokinetic analysis
TLDR
A parent-metabolite population pharmacokinetic (PPK) model is developed to quantify the effects of CYP2D6*10 allele on the pharmacokinetics of iloperidone and its metabolites in Chinese schizophrenia patients, suggesting that the clinical doses of il operidone for patients with CYP 2D 6*10 mutations need to be optimized.
Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
TLDR
In order to introduce iloperidone as an agent for the treatment of schizophrenia, a short overview of the disease and of the most important antipsychotic drugs available or under development will be reported.
Iloperidone for the management of adults with schizophrenia.
TLDR
Data support that when titrated slowly to a therapeutic dosage, iloperidone is generally well tolerated, has a favorable safety profile, and is an effective treatment option in patients with schizophrenia.
Effects of Food on Clinical Pharmacokinetics
TLDR
No rational scientific basis is found to predict the effect of food for a particular chemical entity or a chemical class of therapeutic agents, and a mechanistic understanding of the effects of food may serve as a key to the pharmacokinetic optimisation of patient therapy, both in outpatients and hospitalised patients of various age groups.
An assessment of iloperidone for the treatment of schizophrenia
  • K. Jain
  • Medicine
    Expert opinion on investigational drugs
  • 2000
TLDR
Iloperidone is likely to reach the market in 2001 and has favourable prospects in the atypical antipsychotic market for schizophrenia, which is expanding from US$ 1.5 billion in 2000 to US$ 3 billion in 2005.
Iloperidone—A Second-Generation Antipsychotic for the Treatment of Acute Schizophrenia
TLDR
Iloperidone is an effective treatment for the symptoms of acute schizophrenia in adults and comparative effectiveness with other pharmacologic treatments of schizophrenia, long-term efficacy, and long- term safety is needed.
Iloperidone for the Treatment of Schizophrenia
TLDR
Iloperidone demonstrated efficacy in acute exacerbations and long-term maintenance in adults with schizophrenia and further studies regarding pharmacogenomic testing related to the drug's efficacy and tolerability are needed to justify its routine use in practice.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Pharmacokinetics of risperidone in chronic schizophrenic patients.
TLDR
It is demonstrated that the active moiety (risperidone plus 9-OH-risperinidone) has a half-life of 23 hours and a pool of ris peridone that may allow twice-daily or even once-daily dosing is revealed.
Pharmacological profile of risperidone.
TLDR
The pharmacodynamics and pharmacokinetics of risperidone, an important atypical antipsychotic drug with potent serotonin-5-HT2 and dopamine-D2 receptor blocking effects, are presented and a active metabolite, 9-OH-risperidones, that has a similar pharmacological profile to the patient compound and therefore contributes to the clinical efficacy of the drug.
Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia.
TLDR
Clozapine therapy, performed in conjunction with close haematological monitoring, is indicated for the management of severe and chronic schizophrenia refractory to classic antipsychotic therapy, and in those unable to tolerate such therapy.
Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors.
TLDR
All of the atypical antipsychotic drugs that are clozapine-like have a greater relative affinity in vivo for the 5-HT2 than the D2 receptor, and as a group, the typical antipsychotics drugs tend to be equipped at both receptors.
Effects of atypical antipsychotic agents on social behavior in rodents
TLDR
It is suggested that antipsychotic agents that may be effective in social withdrawal can be identified in this modified social interaction paradigm and that a compound's effectiveness for the treatment of social withdrawal is at least in part due to its relative affinity for binding to dopamine D1 and serotonin 5-HT1A receptors.
Meltzer HY : Characterization of typical and atypical antipsychotic drugs on in vivo occupancy of serotonin and dopamine receptors
  • J Pharmacol Exp Ther
  • 1993
Pharmacological profile of risperidone. Can 1 Psychiatry
  • 1993
The binding of 14C-HP873 to rat, dog and human plasma proteins
  • Document No. TH1D150793,
  • 1993
Conway PC: Antipsychotic activity of IH-indazol-3-ylpiperidine and piperazine analogs of the potential atypical antipsychotic HP 873 (abstract)
  • Am Chem Soc Abstr
  • 1992
HP 873 , a potential atypical antipsychotic agent : pharmacokinetics in rats and dogs
  • Pharmacologist
  • 1991
...
1
2
3
...